PMID- 36273065
OWN - NLM
STAT- MEDLINE
DCOM- 20221114
LR  - 20221114
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Linking)
VI  - 78
IP  - 12
DP  - 2022 Dec
TI  - Efficacy and safety of finerenone in chronic kidney disease associated with type 
      2 diabetes: a systematic review and meta-analysis of randomized clinical trials.
PG  - 1877-1887
LID - 10.1007/s00228-022-03408-w [doi]
AB  - PURPOSE: The main objective was to evaluate the clinical efficacy and safety of 
      finerenone in patients with CKD associated with T2D, especially with regard to 
      renal and cardiovascular protection. METHODS: Eight databases were searched. Mean 
      difference (MD) with 95% confidence interval (CI) of the outcomes and risk ratio 
      (RR) were calculated as the effect measure. RESULTS: Four trials (n = 13,510) 
      were included. Compared to placebo groups, the urinary albumin-to-creatinine 
      ratio (UACR) mean ratio, along with the proportion of patients with a decreased 
      eGFR (>/= 40%) and end-stage kidney disease (ESKD), was significantly lower 
      (MD: -0.30 (95% CI: -0.32, -0.28), p < 0.00001; RR: 0.85 (95% CI: 0.78, 0.93), 
      p = 0.0002; RR: 0.80 (95% CI: 0.65, 0.99), p = 0.04, respectively). Furthermore, 
      the proportion of patients with cardiovascular events (CVs) was significantly 
      lower (RR: 0.88 (95% CI: 0.80, 0.96), p = 0.003). In terms of safety, while the 
      increase in serum potassium concentration and the incidence of hyperkalemia were 
      significantly higher in the finerenone groups (MD: 0.16 (95% CI: 0.07, 0.26), 
      p = 0.00006; RR: 2.03 (95% CI: 1.83, 2.26), p < 0.00001, respectively), the 
      all-cause mortality and the incidence of adverse events (AEs) were similar to 
      placebo (RR: 0.90 (95% CI: 0.80, 1.00), p = 0.05; RR: 1.00 (95% CI: 0.98, 1.01), 
      p = 0.65, respectively). CONCLUSION: The observed renal and cardiovascular 
      benefits of finerenone were significant and did not cause unacceptable 
      side-effects. Finerenone may represent a promising therapeutic tool for CKD 
      associated with T2D.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Bao, Wujisiguleng
AU  - Bao W
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
AD  - Renal Research Institution of Beijing University of Chinese Medicine, Beijing, 
      China.
FAU - Zhang, Mingzhu
AU  - Zhang M
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
AD  - Renal Research Institution of Beijing University of Chinese Medicine, Beijing, 
      China.
FAU - Li, Ning
AU  - Li N
AD  - Emergency Department, Wangjing Hospital of China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Yao, Zhi
AU  - Yao Z
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
AD  - Renal Research Institution of Beijing University of Chinese Medicine, Beijing, 
      China.
FAU - Sun, Luying
AU  - Sun L
AUID- ORCID: 0000-0003-4847-1410
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. 
      luyingsun@outlook.com.
AD  - Renal Research Institution of Beijing University of Chinese Medicine, Beijing, 
      China. luyingsun@outlook.com.
AD  - Fangshan Hospital Beijing University of Chinese Medicine, Beijing, China. 
      luyingsun@outlook.com.
LA  - eng
GR  - 2018YFC1704304/National Key Research and Development Project of China/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20221022
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (finerenone)
RN  - 0 (Naphthyridines)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - *Renal Insufficiency, Chronic/complications/drug therapy
MH  - Naphthyridines/adverse effects
MH  - Potassium/therapeutic use
OTO - NOTNLM
OT  - Chronic kidney disease
OT  - Finerenone
OT  - Meta-analysis
OT  - Systematic review
OT  - Type 2 diabetes
EDAT- 2022/10/23 06:00
MHDA- 2022/11/15 06:00
CRDT- 2022/10/22 23:56
PHST- 2022/09/26 00:00 [received]
PHST- 2022/10/17 00:00 [accepted]
PHST- 2022/10/23 06:00 [pubmed]
PHST- 2022/11/15 06:00 [medline]
PHST- 2022/10/22 23:56 [entrez]
AID - 10.1007/s00228-022-03408-w [pii]
AID - 10.1007/s00228-022-03408-w [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2022 Dec;78(12):1877-1887. doi: 10.1007/s00228-022-03408-w. 
      Epub 2022 Oct 22.